In the current study we set out to study the effect of vanin-1 deficiency on the development of obesity-induced hepatic steatosis and diabetes, as well as the potency of RR6, a novel pantetheinase (vanin) inhibitor, as an anti-diabetic drug using experimental animal models. Here, VNN1 is linked to obesity disorder.